Quoin Pharmaceuticals
QNRX
2 hedge funds and large institutions have $286K invested in Quoin Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
17% less capital invested
Capital invested by funds: $345K → $286K (-$59.3K)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$51.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$51.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$44K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$12K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $227K | +$51.3K | +1 | +25% |
|
|
WS
2
Wedbush Securities
Los Angeles,
California
| $52K | -$51.3K | -1 | -50% |
|
3
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $3K | – | – | – |
|
4
Citigroup
New York
| $1K | – | – | – |
|
|
PA
5
Procyon Advisors
Shelton,
Connecticut
| $1K | – | – | – |
|
6
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
|
AWA
7
Arkadios Wealth Advisors
Atlanta,
Georgia
| $699 | – | – | – |
|
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$44K | -1 | Closed |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$12K | – | – |
|
|
TSS
10
Two Sigma Securities
New York
| – | -$9K | – | – |
|
QNRX Hedge Fund Activity: Q4 2019 in Review
2 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q4 2019, worth a combined $286K — down 17% from $345K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of QNRX and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $51.3K. The largest seller was Wedbush Securities, cutting an estimated $51.3K.
- 2 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q4 2019, down from 3 in Q3 2019.
- Funds reported $286K of Quoin Pharmaceuticals stock for Q4 2019, down 17% quarter-over-quarter.
- 0 funds opened new Quoin Pharmaceuticals positions in Q4 2019 and 1 closed out, a net change of -1 holder.
- The largest Quoin Pharmaceuticals buyer in Q4 2019 was Renaissance Technologies, an estimated $51.3K added.
- The largest Quoin Pharmaceuticals seller in Q4 2019 was Wedbush Securities, an estimated $51.3K sold.
Based on aggregated 13F filings for Q4 2019.